Bribery in the pharmaceutical industry more than 800 million of our commercial bribery a year

Comics: Zhang Jianhui Industry Special, intensified competition, bribery door repeatedly banned the U.S. government to drug companies to open a huge ticket escort new health reform, China? Summary: The US Justice Department has issued a statement announcing that the uk-based pharmaceutical giant, AstraZeneca, has reached agreements with U.S. federal and state-related departments　　Agreed to pay 520 million dollars to settle allegations of its illegal marketing of antipsychotic drugs, 302 million of which will be paid to the federal government, and 218 million dollars to be obtained by state governments. "If there is a 50% profit, it will take the risk, for 100% of the profit, it will dare to trample all the laws of the world, 300% of the profits, it will dare to commit any crime, and even risked hanging." "——— The Complete Works of Marx and Engels," South reporters Meiqin the U.S. Department of Justice announced a statement, the headquarters of the British pharmaceutical giant AstraZeneca company has been with the U.S. federal and state departments to reach an agreement,　　Agreed to pay 520 million dollars to settle allegations of its illegal marketing of antipsychotic drugs, 302 million of which will be paid to the federal government, and 218 million dollars to be obtained by state governments. Analysts believe that the reason for the U.S. government's big ticket is related to the new U.S. health reform, "Reducing industry fraud is an important part of Obamacare." Reducing medical costs by reducing drug marketing is an important way for the Obama administration to implement health reform. "The US government has taken a heavy toll on corruption in the medical world. The U.S. Department of Justice has accused the company of promoting it to patients with Alzheimer's disease, anxiety, dementia, depression and post-traumatic stress disorder, and the FDA has not approved the idea that it is used to treat the disease," it said.　　In addition, the Justice Department has accused AstraZeneca of paying doctors to sign articles on the therapeutic efficacy of the company, paying doctors for travel expenses and paying doctors to deliver promotional speeches, which violate federal kickbacks. In contrast to the fines the US pharmaceutical giants have traditionally suffered for illegal marketing, AstraZeneca's ticket is not high, and Pfizer, which has been punished by 2.3 billion of dollars for improper marketing of 13 drugs last September, has become the biggest ticket ever issued in the United States for over-the-counter prescriptions.　　Then, in January this year, the company was sued for paying a total of tens of millions of dollars in kickbacks, prompting nursing homes to sell more of Johnson's anti-schizophrenia drugs and other medications to patients.　　U.S. Attorney General Eric said in a statement that the drug companies ' illegal practices and false declarations against the medical system were endangering public health and the impartiality of medical decisions, and that the justice sector "would never condone such behaviour" by taking billions of of dollars directly from the taxpayer's purse. Holder said the number of health care fraud cases handled by the Justice Department reached a record high in 2009. In the past 15 months, the U.S. Department of Justice has been chasing federal Treasuries under the False Declaration Act in health Care fraud casesBack a loss of 2.8 billion dollars.　　The Ministry of Justice will strengthen its cooperation with the Department of Health and Human Services to further combat health care fraud. The company said on the same day that it was in the best interests of the company to reach a settlement agreement. However, the company denies wrongdoing by the US Justice Department.　　It is one of the most-sold antipsychotic drugs in the United States, with sales reaching $3.4 billion trillion in 2009. March 23 This year, U.S. President Barack Obama formally signed the health Care reform bill. Reducing industry fraud is an important part of Mr Obama's health reform. By reducing drug marketing and reducing medical costs, it is an important means for the Obama administration to implement health reform, which has become the target of a US government attack.　　The survey of AstraZeneca is a central part of the U.S. government's crackdown on corruption in the healthcare sector. In the future, U.S. regulators, in addition to continuing to focus on overseeing several of the country's largest pharmaceutical companies, are also targeting doctors with kickbacks and improper profits in the hope of overhauling the medical market that has been the subject of frequent criminal incidents in recent years.　　The United States Department of Justice to Aslitay "a ticket", once again demonstrated the Government's firm determination to deal with illegal drug companies. The Chinese medicine commercial bribery is nearly 800 million in a year. China's new health reform is groping forward, into the 2010, public hospital reform has become a continuing constraint, hospitals, doctors, drugs ... Ultimately, it is a matter of interest.　　A regular three-a hospital, more than 40% of the income from the sale of drugs, the doctor's income and prescription drugs are closely related, so the relationship between the entanglements, to be clear, indeed many "critical" blocked.　　Liu Renbin, a third hospital affiliated to Sun Yat-sen University, told reporters that medicine is a special commodity, it is difficult for ordinary consumers to have a clear independent discriminant ability, the doctor occupies a strong dominant power, the choice of which medicine, how the efficacy, what side effects, and so on, need professional doctor's guidance.　　Fangming, head of regional sales at a drug company, said that the one-way decision was leading to a proliferation of commercial bribery in drug sales, especially in large hospitals. It is worth mentioning that at home, there is too much imitation drugs, competition and homogeneous competition is too intense. Light domestic drug enterprises as many as 4,000, coupled with a number of multinational enterprises to join, competition is fierce, and some have to use the "gray" means to stimulate sales. "As a result of commercial bribery embezzled state assets of about 772 million yuan a year, accounting for the national pharmaceutical industry's annual tax revenue of 16%."　　"This official survey data has been quoted from all walks of life, under the current medical system, the use of the right to talk about drugs is mainly in the hands of doctors, which also led to high drug prices and other problems." Before this, Guangdong pharmaceutical sunshine Purchase, there are domestic small and medium-sized pharmaceutical companies complained that the participation of the evaluation of hospital experts by those rich foreign or large enterprises "bought", resulting in other enterprises of the product was unsuccessful hospital procurement, but also in the pricing of pharmaceutical companies will be medical meetings, medical research and other costs to pass to the retail price, And ultimately it is the patient who buys this part of the benefit of the list. It's aOne of the main reasons for the criticism of commercial bribery in the field of medicine and health. Lin Jing-wen, a researcher at the Institute of Public Communications at Sun Yat-sen University, said the lure of huge commercial profits in China was an incentive for companies to bribe.　　In the face of huge market and profit space, many companies are difficult to be alone, therefore, bribery naturally becomes the key to open the business door, so the domestic market more need to strengthen the blow to commercial bribery.　　Yan (a pseudonym), who has been immersed in multinational pharmaceutical companies for more than eight years, told reporters the drug industry bribery is indeed more common, as a pharmaceutical enterprise, in the determination of drug prices, in addition to the material costs, human costs into consideration, but also to consider agents rebate, into the hospital after a variety of channel costs, including large chain pharmacies shelves fees and so on.　　Yan told reporters, production enterprises and agents between the rebate has been public, agents can usually get the drug price of 10%-15% rebate, in fact, this is also a normal profit margins, and drugs into the hospital after the "public relations" cost is not transparent. Related news emerging market growth strong transnational drug companies envious the latest forecast, the BRICS (Brazil, Russia, India and China), Turkey, South Korea and Mexico, the pharmaceutical market is expected to grow strongly, 2010 will be the cumulative growth 12%~14%,2013 year will reach 13%~16%.　　The Chinese medicine market is expected to grow by more than 20% a year. In response to these global changes, multinational pharmaceutical companies have long begun to Rimini, or to acquire the dominant companies in emerging markets, or to increase investment to expand emerging market share, or to build global research centers in emerging markets to take advantage of the cost advantages of emerging markets and so on.